Loading
Adding pemetrexed to cisplatin lengthened survival by almost three months in pleural mesothelioma, making platinum-pemetrexed the first, and for many years the only, standard chemotherapy for the disease.
Phase 3 trial of 456 chemotherapy-naive patients with malignant pleural mesothelioma randomised to pemetrexed plus cisplatin or cisplatin alone, with folic acid and vitamin B12 supplementation introduced part-way through to reduce toxicity.
Median overall survival was 12.1 versus 9.3 months, response rate 41.3 versus 16.7 percent, and lung function and symptoms were better with the combination; vitamin supplementation markedly reduced severe toxicity.
Platinum-pemetrexed remains the chemotherapy backbone in mesothelioma, now combined with pembrolizumab or bevacizumab, or replaced by dual immunotherapy in non-epithelioid disease.
Shares Peritoneal mesothelioma, Journal of Clinical Oncology.
Shares Pleural mesothelioma, Pemetrexed, Cisplatin.
Shares Pemetrexed, Cisplatin.
Shares Pemetrexed, Cisplatin.
Shares Pemetrexed, Cisplatin.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/